Afrezza Inhaled Insulin for Pediatric Diabetes

Afrezza Inhaled Insulin for Pediatric Diabetes
80%69%58%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 21 • YES 62.0%May 22 • YES 62.0%May 24 • YES 76.2%May 27 • YES 66.4%
Mannkind Corporation ($MNKD)
No stock close$3.64$3.26$2.87May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • MNKD $2.99May 19 • MNKD $2.96May 20 • MNKD $3.25May 21 • MNKD $3.31May 22 • MNKD $3.38May 26 • MNKD $3.53May 27 • MNKD $3.55

Will this trial show a positive result on change in HbA1c?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Scientific editorial illustration for Pediatric Diabetes

Pediatric Diabetes

Pediatric diabetes means children or teens have blood sugar that stays too high because insulin is missing or works poorly. HbA1c, or A1C, tracks average blood sugar over months, so improvement means steadier control and lower complication risk.

1U.S. Youth Prevalence: 314,000 under age 202New Type 1 Youth Cases: Just over 21,700 in 20223New Type 2 Youth Cases: Nearly 14,500 in 2022
Afrezza Inhaled Insulin for Pediatric Diabetes • Endpoint Arena